According to the docket posted and the Company's Form 10-Q for the quarterly period ended June 30, 1998, plaintiff and the defendant have agreed that plaintiff will voluntarily dismiss all claims against all defendants in that action. On May 18, 1998, the Stipulation and Order by Judge Ronald M. Whyte dismissed the case.

The complaint charges Cor and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Specifically, the complaint alleges that throughout the Class Period, defendants caused Cor to disseminate, through public statements and SEC filings, false and misleading statements about the results of the clinical trials for its drug Integrilin for use in patients with unstable angina and non-Q-wave myocardial infarction. The complaint further alleges that defendants engaged in this wrongful conduct for the purpose of allowing the Company to raise more than $59 million in proceeds by completing a public offering of Cor common stock at artificially inflated prices.